IP Library Granted Patent US 7,741,340
Granted Patent B2
US 7,741,340 · App. 10/988,428 · Granted Jun 22, 2010

Hydroxy piperidine derivatives to treat gaucher disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,741,340
App. No.
10/988,428
Granted
Jun 22, 2010
Kind
B2
Abstract

The present invention provides novel hydroxy piperidine (HP) derivatives having (i) a positive charge at the position corresponding to the anomeric position of a pyranose ring; (ii) a short, flexible linker emanating from the corresponding position of the ring oxygen in a pyranose; and (iii) a lipophilic moiety connected to the linker and pharmaceutically acceptable salts thereof. The linker can be absent if the lipophilic moiety corresponds to a hydrocarbon chain with a linear length of 6 or more carbons. The present invention further provides a method for treating individuals having Gaucher disease by administering the novel HP derivative as “active-site specific chaperones” for the mutant glucocerebrosidase associated with the disease.

Claims (14)

1. A method of enhancing in a mammalian cell the activity of glucocerebrosidase, comprising contacting the cell with at least one compound in an amount effective to enhance the activity of glucocerebrosidase, wherein the effective amount does not inhibit glucocerebrosidase activity, and wherein the compound is represented by the following formula:

wherein A is a carbon;

B is a hydrogen;

R 1 is a hydrogen, substituted or unsubstituted: alkyl;

R 2 is an optional C1-C6 alkyl;

R 5 is a hydroxymethyl;

L is a 1-12 carbon atom alkyl or benzyl;

R 2 and L together have at least 4 carbon atoms;

and pharmaceutically acceptable salts thereof.

2. The method of claim 1 , wherein the compound is (3R, 4R, 5R, 6S) -5-(hydroxymethyl)-6-n-butyl-3,4-dihydroxypiperdine.

3. The method of claim 1 , wherein the compound is (3R, 4R, 5R, 6S) -5-(hydroxymethyl)-6-n-hexyl-3,4-dihydroxypiperdine.

4. The method of claim 1 , wherein the compound is (3R, 4R, 5R, 6S) -5-(hydroxymethyl)-6-n-heptyl-3,4-dihydroxypiperdine.

5. The method of claim 1 , wherein the compound is (3R, 4R, 5R, 6S) -5-(hydroxymethyl)-6-n-octyl-3,4-dihydroxypiperdine.

6. The method of claim 1 , wherein the compound is (3R, 4R, 5R, 6S) -5-(hydroxymethyl)-6-n-nonyl-3,4-dihydroxypiperdine.

Assignments (2)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2005
From: FAN, JIAN-QIANG; ZHU, XIAOXIANG; SHETH, KAMLESH
To: AMICUS THERAPEUTICS INC.
Reel/Frame 015647/0227 →